News National MS Society Invests in Clinical Development of Human Antibody for Progressive Forms of MS National MS Society Invests in Clinical Development of Human Antibody for Progressive Forms of MS by Patricia Inacio, PhD | October 31, 2018 Share this article: Share article via email Copy article link Fast Forward, a nonprofit subsidiary of theĀ National Multiple Sclerosis Society, will invest up to $330,000 to advance the clinical development of an antibody that was shown to lessen inflammation and nerve cell damage in a multiple sclerosisĀ (MS) mouse model. The funding will help develop the antibody (aĀ protein the immune system uses to neutralize pathogens such as bacteria and viruses) in order to have properties more similar to those found in humans (a humanized antibody), and to test its therapeutic potential in people with MS. Therapies able to protect the nervous system are needed, especially by those with progressive forms of MS, an area in particular need of therapeutic strategies to halt the damage to the nervous system triggered by chronic neuroinflammation. The antibody, being developed by MedaRed, followsĀ the early workĀ of the companyās co-founder Katerina Akassoglou, PhD, at theĀ Gladstone InstitutesĀ and theĀ University of California San Francisco. āWe are excited to see the development of this antibody accelerate toward a breakthrough for progressive MS,ā Mark Allegretta, PhD, vice president of research at the National MS Society, said in aĀ press release. āThis funding will help MedaRed take a key step for translating their important findings toward a clinical trial in people with progressive MS.ā Akassoglouās team developed an antibody that targets a blood-clotting factor, called fibrin, previously shown to trigger inflammation in the brain. Fibrin has been detected in active and chronic brain lesions of MS patients. Want to learn more about the latest research in MS? Ask your questions in our research forum. They designed their antibody to selectively target a specific region within the fibrin protein known to activate the immune response. This assured that the proteinās region responsible for the blood-clotting effectĀ remained intact. Using a mouse model of MS, researchers showed that treatment with their newly-developed antibody halted activation ofĀ inflammation and oxidative stress, two potential sources of toxic chemicals that may contribute to nerve cell death.Ā The same was seen in a mouse model of Alzheimerās disease. Moreover, the antibody reduced the activation and accumulation of inflammatory cells in the spinal cord, and lessened nerve cell damage and demyelination (loss of myelin) of nerve fibers, a hallmark of MS. These preclinical data were reported in an article titled āFibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration,ā published in the journalĀ Nature Immunology. āThe funding from the National MS Society accelerates the transition of this important research discovery into the clinicā said Edward Spack, PhD, president of MedaRed. āWe look forward to accomplishing this key step in drug development through the support of the Society, and improving the health of people with MS.ā Print This Page About the Author Patricia Inacio, PhD Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship. Tags antibody, demyelination, Fast Forward, inflammation, National Multiple Sclerosis Society
May 2, 2024 News by Marisa Wexler, MS Immigrants to Canada see MS risk rising with time in country: Study
April 30, 2024 News by Andrea Lobo, PhD Committee favors approval of under-the-skin Ocrevus in Europe